Disclosures for "Safety and Effectiveness of Efgartigimod in Japanese Patients With Generalized Myasthenia Gravis by Serological Profiles: Analysis of Post-marketing Surveillance"
-
Mr. Teranishi has received personal compensation for serving as an employee of argenx.
-
Mr. Aoyagi has received personal compensation for serving as an employee of argenx. Mr. Aoyagi has stock in argenx.
-
Mr. Harada has received personal compensation for serving as an employee of argenx K.K..
-
Mitsuru Watanabe has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharma, Mitsubishi Tanabe Pharma, UCB Japan. Mitsuru Watanabe has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion Pharma, Argenx, UCB Japan, Novartis Pharma, Biogen Japan, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Viatris, and Daiichi Sankyo. The institution of Mitsuru Watanabe has received research support from Japan. Mitsuru Watanabe has received publishing royalties from a publication relating to health care.